- Home
- LIPO vs SNOA Comparison
LIPO vs SNOA Comparison
Compare LIPO & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIPO
- SNOA
- Stock Information
- Founded
- LIPO 2005
- SNOA 1999
- Country
- LIPO United States
- SNOA United States
- Employees
- LIPO N/A
- SNOA N/A
- Industry
- LIPO Biotechnology: Pharmaceutical Preparations
- SNOA Biotechnology: Pharmaceutical Preparations
- Sector
- LIPO Health Care
- SNOA Health Care
- Exchange
- LIPO Nasdaq
- SNOA Nasdaq
- Market Cap
- LIPO 3.1M
- SNOA 3.6M
- IPO Year
- LIPO 2022
- SNOA 2007
- Fundamental
- Price
- LIPO $3.14
- SNOA $2.40
- Analyst Decision
- LIPO Strong Buy
- SNOA
- Analyst Count
- LIPO 1
- SNOA 0
- Target Price
- LIPO $16.00
- SNOA N/A
- AVG Volume (30 Days)
- LIPO 6.6M
- SNOA 52.9K
- Earning Date
- LIPO 02-28-2025
- SNOA 02-05-2025
- Dividend Yield
- LIPO N/A
- SNOA N/A
- EPS Growth
- LIPO N/A
- SNOA N/A
- EPS
- LIPO N/A
- SNOA N/A
- Revenue
- LIPO $483,533.00
- SNOA $13,973,000.00
- Revenue This Year
- LIPO N/A
- SNOA $23.89
- Revenue Next Year
- LIPO N/A
- SNOA $25.45
- P/E Ratio
- LIPO N/A
- SNOA N/A
- Revenue Growth
- LIPO 0.78
- SNOA 13.51
- 52 Week Low
- LIPO $2.21
- SNOA $2.30
- 52 Week High
- LIPO $12.00
- SNOA $9.40
- Technical
- Relative Strength Index (RSI)
- LIPO 48.05
- SNOA 36.06
- Support Level
- LIPO $3.35
- SNOA $2.30
- Resistance Level
- LIPO $4.69
- SNOA $2.62
- Average True Range (ATR)
- LIPO 0.62
- SNOA 0.12
- MACD
- LIPO -0.02
- SNOA -0.02
- Stochastic Oscillator
- LIPO 13.31
- SNOA 21.59
About LIPO Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410 which can be helpful in treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.
About SNOA Sonoma Pharmaceuticals Inc.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.